These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24790218)

  • 1. Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
    van Asselt SJ; Oosting SF; Brouwers AH; Bongaerts AH; de Jong JR; Lub-de Hooge MN; Oude Munnink TH; Fiebrich HB; Sluiter WJ; Links TP; Walenkamp AM; de Vries EG
    J Nucl Med; 2014 Jul; 55(7):1087-92. PubMed ID: 24790218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
    van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
    Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    van Es SC; Brouwers AH; Mahesh SVK; Leliveld-Kors AM; de Jong IJ; Lub-de Hooge MN; de Vries EGE; Gietema JA; Oosting SF
    J Nucl Med; 2017 Jun; 58(6):905-910. PubMed ID: 28082434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
    Oosting SF; Brouwers AH; van Es SC; Nagengast WB; Oude Munnink TH; Lub-de Hooge MN; Hollema H; de Jong JR; de Jong IJ; de Haas S; Scherer SJ; Sluiter WJ; Dierckx RA; Bongaerts AH; Gietema JA; de Vries EG
    J Nucl Med; 2015 Jan; 56(1):63-9. PubMed ID: 25476536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
    Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
    J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 89Zr-bevacizumab PET imaging in primary breast cancer.
    Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
    J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
    Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
    Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
    Chen JL; Appelbaum DE; Kocherginsky M; Cowey CL; Rathmell WK; McDermott DF; Stadler WM
    Cancer Med; 2013 Aug; 2(4):545-52. PubMed ID: 24156027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Drug Imaging:
    Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
    J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
    J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
    Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
    Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
    den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
    J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors.
    Yao JC; Phan AT; Hess K; Fogelman D; Jacobs C; Dagohoy C; Leary C; Xie K; Ng CS
    Pancreas; 2015 Mar; 44(2):190-7. PubMed ID: 25426617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-PET Imaging to Assess Target Engagement: Experience from
    Menke-van der Houven van Oordt CW; McGeoch A; Bergstrom M; McSherry I; Smith DA; Cleveland M; Al-Azzam W; Chen L; Verheul H; Hoekstra OS; Vugts DJ; Freedman I; Huisman M; Matheny C; van Dongen G; Zhang S
    J Nucl Med; 2019 Jul; 60(7):902-909. PubMed ID: 30733323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography.
    Golestani R; Zeebregts CJ; Terwisscha van Scheltinga AG; Lub-de Hooge MN; van Dam GM; Glaudemans AW; Dierckx RA; Tio RA; Suurmeijer AJ; Boersma HH; Nagengast WB; Slart RH
    Mol Imaging; 2013 Jun; 12(4):235-43. PubMed ID: 23651501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
    Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
    J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
    Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
    Terwisscha van Scheltinga AG; van Dam GM; Nagengast WB; Ntziachristos V; Hollema H; Herek JL; Schröder CP; Kosterink JG; Lub-de Hoog MN; de Vries EG
    J Nucl Med; 2011 Nov; 52(11):1778-85. PubMed ID: 21990576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
    Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
    J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.